drug
TECENTRIQ
updated 3mo agoby Genentech Inc
community read0 votes
🐶 often sniffed alongside
top 8- drugatezolizumab178 co-mentions · 46 sources
- tagApproval176 co-mentions · 44 sources
- companyGenentech Inc88 co-mentions · 44 sources
- drugTECENTRIQ HYBREZA20 co-mentions · 5 sources
- drug(atezolizumab + hyaluronidase (human recombinant))10 co-mentions · 5 sources
- tagOncology5 co-mentions · 2 sources
- companyDana-Farber Cancer Institute Inc1 co-mentions · 1 sources
- tagHepatology1 co-mentions · 1 sources
all catalysts(0)
nothing on the calendar yet
Trials studying TECENTRIQ
- phase1A Study of Valemetostat in Combination With Atezolizumab in People With Lung Cancer
- phase3A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study
- phase2Safety and Activity of PolyPEPI1018 Plus Atezolizumab in Colorectal Cancer.
- phase2DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers
- phase2Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
- phase2A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
- phase2A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab
- phase2A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
News(7)
- Summit, Merck must navigate new regulatory terrain in China-first cancer landscapeSummit Therapeutics revealed positive Western data last week from a Phase 3 trial of lung cancer candidate ivonescimab. In a flipped geographical clinical trials landscape, what more will be requir…biospace · 16d ago
- Roche drops TCE for lupus, but hasn’t given up on autoimmune cell therapiesRoche may have scrapped work on a T-cell engager being evaluated for lupus, but the company’s head of pharma told Fierce that still has a strategy for developing cell therapies for autoimmune disea…fiercebiotech · 20d ago
- Design Therapeutics' Friedreich's ataxia data; Vincentage's obesity results from ChinaPlus, news about Enhertu and Tecentriq. 💪 Design Therapeutics shares Phase 1/2 data in Friedreich's ataxia: The California biotech’s DT-216P2 given at 1 mg/kg led to an average 6.4-point improveme…endpoints · 2mo ago
- Dr Hafron on the FDA Approval of Adjuvant Atezolizumab in MRD+ MIBCJason Hafron, MD, discusses the significance of the FDA approval of adjuvant atezolizumab for MRD+ muscle-invasive bladder cancer.onclive · 2mo ago
- FDA Approves Adjuvant Atezolizumab for MRD+ Muscle-Invasive Bladder CancerThe FDA approved adjuvant atezolizumab for muscle-invasive bladder cancer with circulating tumor DNA molecular residual disease.onclive · 2mo ago
- Track the Lung Cancer Abstracts That are Gaining Attention at ASCO 2026Read on to see what data are poised to shape clinical discussions and decision-making in lung cancer at 2026 ASCO Annual Meeting in Chicago, Illinois.onclive · 3mo ago
- Simlukafusp Alfa Regimens Show Manageable Safety and Activity But Do Not Outperform SOC in Metastatic RCCSimlukafusp alfa plus atezolizumab with/without bevacizumab was safe and active but did not improve upon responses with SOC treatments in metastatic RCC.onclive · 3mo ago
Data sources
last refreshed 6m ago
Found something off?
comments(0)
5-min edit window · permanent after that